Randomized phase II study of a KRAS G12D inhibitor plus erlotinib in basal-like pancreatic adenocarcinoma

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

TryWhat does it aim to do?Which model or cohort does it use?